Astellas Pharma Sells Grand Island, N.Y. Plant to APP Pharmaceuticals In Consolidation Move
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas Pharma said Sept. 5 it had sold its Grand Island, N.Y. plant that manufactures atopic dermatitis treatment Protopic (tacrolimus) to APP Pharmaceuticals of Schaumburg, Ill
You may also be interested in...
Astellas And Maxygen Ink Global Development Deal For Autoimmune Candidate MAXY-4
Maxygen's early-July decision to bear down on advancing its lead neutropenia compound and next-generation CTLA4-Ig drugs, letting Bayer take its hemophilia program, is paying off with Astellas, which signed a global deal that brings $10 million up front
Astellas And Maxygen Ink Global Development Deal For Autoimmune Candidate MAXY-4
Maxygen's early-July decision to bear down on advancing its lead neutropenia compound and next-generation CTLA4-Ig drugs, letting Bayer take its hemophilia program, is paying off with Astellas, which signed a global deal that brings $10 million up front
U.S. FDA Inspected “Wrong” Heparin API Manufacturer – Compliance Official
U.S. FDA failed to inspect a Chinese API manufacturer that may be linked to a recent heparin safety scare because the wrong Chinese firm was entered into an agency database, a compliance official said Feb. 18